期刊
FRONTIERS IN ONCOLOGY
卷 10, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2020.586752
关键词
Epstein-Barr virus (EBV); gastric cancer; CD3; CD68; immune microenvironment
类别
资金
- National High Technology Research and Development Program of China (863 Program) [2014AA020603]
- Beijing-Municipal Science and Technology Project [D171100006517000]
- Double First Class disciplinary development Foundation of Peking University [BMU2019LCKXJ011]
- Mission Talent Program [SML20151001]
- Capital funds for health improvement and research [2018-2-103]
- Three-year-rotating Budget Program
- Beijing Municipal Commission of Health and Family Planning
- Clinical Medicine Development Special Funding of BeijingMunicipal Administration [ZYLX201701]
- National Natural Science Foundation of China [81872502, 81972758]
- Interdisciplinary Medicine Seed Fund of Peking University [BMU2018MX020]
- Beijing Municipal Administration of Hospitals' Youth Program [QML20181102]
- Key Laboratory of Carcinogenesis and Translational Research, the Ministry of Education/Beijing
- Beijing Municipal Administration of Hospitals Incubating Program [PX2019040]
- Science Foundation of Peking University Cancer Hospital [2017-23, 2017-28, 2020-6]
Epstein-Barr virus-associated gastric cancer patients are characterized by younger age, low-differentiated adenocarcinoma, and less vascular invasion. Increased infiltration of immune cells affects patient prognosis, particularly in EBVaGC patients with higher CD3(+) T lymphocyte density, leading to longer survival.
Background Epstein-Barr virus-associated gastric cancer(EBVaGC)has a unique tumor immune microenvironment. We performed a comprehensive analysis of the tumor-infiltrating immune cells in a cohort of EBVaGC in a Chinese population. Methods Epstein-Barr encoding region (EBER) in situ hybridization was performed in 1,328 consecutive cases of surgically resected GC. Densities of immune cells, including T cells, B cells, natural killer cells, and macrophages from the patients were calculated after immunohistochemical staining with CD3, CD20, CD57, and CD68 antibodies in tissue microarrays, respectively. Results EBVaGC patients accounted for 4.1% (55 of 1,328) cases in the overall population. The average age of patients with EBVaGC was lower than that of non-EBVaGC patients. Histologically, EBVaGC patients exhibited poorly differentiated adenocarcinoma (P = 0.004) and lower frequency of vascular invasion (P = 0.034). The density of CD3(+) T lymphocytes (CD3, 23.84 +/- 14.49 vs. 12.76 +/- 8.93, P < 0.001) and CD68(+) macrophages (CD68, 9.73 +/- 5.25 vs. 5.44 +/- 4.18, P < 0.001) was significantly higher in EBVaGC patients. CD3(+) T cell density predicted better 5-year overall survival of EBVaGC patients (P = 0.022). Conclusions EBVaGC patients were younger with low-differentiated adenocarcinoma and less vascular invasion. Increased infiltration of multiple immune cells affected the prognosis of patients, especially EBVaGC patients with more CD3(+) T lymphocytes, who survived longer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据